Propranolol decreases fear expression by modulating fear memory traces

Post-traumatic stress disorder (PTSD) can develop following a traumatic event and results in heightened, inappropriate fear and anxiety. Although approximately 8% of the United States population suffers from PTSD, only two drugs have been approved by the FDA to treat it, both with limited efficacy. Propranolol, a non-selective β-adrenergic antagonist, has shown efficacy in decreasing exaggerated fear, and there has been renewed interest in using it to treat fear disorders.

Source: Biological Psychiatry - January 19, 2021 Category: Psychiatry Authors: Sofia Leal Santos, Michelle Stackmann, Andrea Mu ñoz Zamora, Alessia Mastrodonato, Allegra V. De Landri, Nick Vaughan, Briana K. Chen, Marcos Lanio, Christine A. Denny Tags: Archival Report Source Type: research